Home
HelpMayo Test ID ADULT Adulterants Survey, Random, Urine
Ordering Guidance
For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody information, see ADLTX / Adulterants Survey, Chain of Custody, Random, Urine.
Specimen Required
Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 1.5 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Additional Information: Submitting less than 1.5 mL may compromise the ability to perform all necessary testing.
Useful For
Assessment of possible adulteration of a urine specimen submitted for drug of abuse testing
Providing the creatinine concentration for normalization purposes
Testing Algorithm
For more information see Adulterant Survey Algorithm.
Special Instructions
Method Name
Spectrophotometry (SP)
Reporting Name
Adulterants Survey, USpecimen Type
UrineSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days | ||
| Ambient | 72 hours |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Specimen adulteration is the manipulation of a sample that may cause false-negative test results for the presence of drugs of abuse. Common adulterants that may affect testing are water, soap, bleach, vinegar, oxidants, and salt. The adulteration testing includes assessment of creatinine concentration, pH, urine specific gravity, presence or absence of an oxidant, and presence or absence of nitrite.
Reference Values
Cutoff concentrations
Oxidants: 200 mg/L
Nitrites: 500 mg/L
Interpretation
For information see Adulterant Survey Algorithm.
Cautions
No significant cautionary statements
Method Description
All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement.(Package inserts: Specimen Validity Test Creatinine. Roche Diagnostics; V3.0, 08/2015; Specimen Validity Test Nitrite. Roche Diagnostics; V3.0, 08/2018, Specimen Validity Test Oxidant. Roche Diagnostics; V 3.0, 08/2018; Specimen Validity Test pH Roche Diagnostics; V3.0, 02/2019, Specimen Validity Test Specific Gravity. Roche Diagnostics; V4.0, 08/2022)
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 2 daysSpecimen Retention Time
2 weeksPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ADULT | Adulterants Survey, U | 58714-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 20606 | Creatinine, U | 2161-8 |
| 22312 | Specific Gravity | 5810-7 |
| 23509 | pH | 2756-5 |
| 23511 | Oxidants | 58714-7 |
| 23510 | Nitrites | 32710-6 |
| 30914 | Comment | 48767-8 |
Clinical Reference
1. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA). Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register. 2017 January 23;82(13):FR 7920. Accessed July 15, 2024. Available at www.samhsa.gov/sites/default/files/workplace/frn_vol_82_7920_.pdf
2. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA). Drug-Free Workplace Programs: Employer Resources. Updated October 11, 2023. Accessed July 15, 2024. Available at www.samhsa.gov/workplace/resources
3. US Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA). Mandatory Guidelines for Federal Workplace Drug Testing Programs. Updated October 12, 2023. Accessed July 15, 2024. Available at www.federalregister.gov/documents/2023/10/12/2023-21734/mandatory-guidelines-for-federal-workplace-drug-testing-programs